

InvestorTalk Alert: Brent Willis from Voyageur Pharmaceuticals Ltd. to host on Thursday, September 12, 2024

written by Raj Shah | September 11, 2024

InvestorNews is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Thursday, September 12th, at 9 AM EST, featuring Brent Willis, President, CEO, and Director of [Voyageur Pharmaceuticals Ltd.](#) (TSXV: VM). To participate in this engaging discussion, please [click here](#)

Currently, Voyageur Pharmaceuticals holds [139,473,176](#) shares outstanding and has a market capitalization of [CAD\\$6,973,659](#).

In preparation for tomorrow's InvestorTalk, here are the three most recent news releases from Voyageur Pharmaceuticals for your review, which are listed below:


- September 05, 2024 – Voyageur Introduces Five New Barium Contrast Formulations Setting New Standards in Medical Imaging Industry – [click here](#)
- July 09, 2024 – Voyageur Pharmaceuticals Grants Deferred Share Units – [click here](#)
- June 11, 2024 – Testing to Begin of Radiology Endohedral Fullerenes, a Milestone in Nanotechnology & Drug Development – [click here](#)

5-Data Points from Voyageur Pharmaceuticals' most recent news

release titled, *Voyageur Introduces Five New Barium Contrast Formulations Setting New Standards in Medical Imaging Industry*:

1. **New Product Line Introduction:** Voyageur has developed five new Health Canada licensed barium contrast products under the brands “Vision” and “Smooth,” which are designed to improve medical imaging diagnostics.
2. **FDA 505(b)(2) Drug Pathway:** The new products will be submitted under the FDA’s 505(b)(2) drug pathway, allowing for faster approvals using existing data, reducing costs and timelines compared to a full New Drug Application (NDA) process.
3. **Patient Trials and Clinical Testing:** Voyageur has completed test pilot batches and is moving to the final phase of clinical testing, including patient trials for X-ray and CT, expected to last two months, followed by market launches in Canada and internationally.
4. **Competitive Shift:** By transitioning from generic to advanced formulations, Voyageur aims to create intellectual property, enhancing its competitive position and offering long-term advantages in the medical imaging market.
5. **Vertically Integrated Business Model:** Voyageur controls its raw materials through its 100% owned Frances Creek barium sulphate project, aiming to be the first fully vertically integrated company in the radiology contrast media market, ensuring cost efficiency and quality from raw material to final product.

(09.11.2024 at 6:00 AM EST, [Source](#))



For more information on Voyageur Pharmaceuticals Ltd., [click here](#)

For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.